Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Felix Gonzalez-Torres' and Gregg Bordowitz’s works express their experiences of living through a pandemic and subsequent social change and draw out key human rights themes.
AMA J Ethics. 2020;22(9):E821-829. doi:
10.1001/amajethics.2020.821.
Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi:
10.1001/amajethics.2018.881.
Professional society guidelines can be used to set standards for clinical practice instead of government. This approach could help if federal or state policymakers view discarding embryos as ethically equivalent to abortion.
AMA J Ethics. 2018;20(12):E1160-1167. doi:
10.1001/amajethics.2018.1160.
Prevention efforts can marginalize patients by stigmatizing certain behaviors, so distinguishing individual professionals’ preferences about those behaviors is critical.
AMA J Ethics. 2019;21(6):E536-539. doi:
10.1001/amajethics.2019.536.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?